Simplify Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Simplify Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,242	Closed	-$296K	–	147
2026 Q1	$296K	Buy	+20,242	New	+$323K	﹤0.01%	122

Other funds holding CRVS

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Avity Investment Management Greenwich, Connecticut $1.57B AUM 35.56% 1-Year Est. Return

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Simplify Asset Management's CRVS Position: Q2 2026 in Review

Simplify Asset Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 20,242 shares — an estimated $296K sold.

Simplify Asset Management first reported a position in CRVS in Q1 2026 and held it in 1 quarter. The position peaked at $296K in Q1 2026. 8 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Simplify Asset Management reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Simplify Asset Management sold 20,242 Corvus Pharmaceuticals shares in Q2 2026, an estimated $296K.
Simplify Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Simplify Asset Management's Corvus Pharmaceuticals position peaked at $296K in Q1 2026.
8 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Simplify Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.